<p>Relay Therapeutics（纳斯达克代码：RLAY - 获取免费报告）在周三发布的报告中，Citizens Jmp 的股票分析师将其目标价格从 19.00 美元上调至 21.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “市场表现优于大盘”。Citizens Jmp 的目标价格暗示该股票相较于之前的收盘价有 73.99% 的潜在上涨空间。</p>
<p>获取 <strong>Relay Therapeutics</strong> 的提醒：</p>
<ul>
<li>解锁医疗保健领域的人工智能投资机会</li>
</ul>
<p>其他股票分析师最近也对该公司发布了报告。瑞银集团在周二的研究报告中将 Relay Therapeutics 的目标价格设定为 26.00 美元。花旗集团在周三的研究报告中重申了对 Relay Therapeutics 股票的 “跑赢大盘” 评级。HC Wainwright 在 4 月 29 日的研究报告中将 Relay Therapeutics 的目标价格从 19.00 美元上调至 25.00 美元，并给予该公司 “买入” 评级。富国银行在 4 月 28 日的研究报告中将 Relay Therapeutics 的目标价格从 17.00 美元上调至 21.00 美元，并给予该股票 “增持” 评级。最后，Raymond James Financial 在周二的报告中重申了对 Relay Therapeutics 股票的 “强力买入” 评级。一位股票研究分析师对该股票给予了 “强力买入” 评级，八位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 22.60 美元。</p>
<p><strong>阅读我们关于 RLAY 的最新研究报告</strong></p>
<h2>Relay Therapeutics 股票下跌 0.2%</h2>
<p>周三，RLAY 股票开盘价为 12.07 美元。该公司的 50 日移动平均线为 12.56 美元，200 日移动平均线为 9.62 美元。该股票的市值为 23.1 亿美元，市盈率为-7.69，贝塔值为 1.74。Relay Therapeutics 的 52 周低点为 2.75 美元，52 周高点为 17.32 美元。</p>
<p>Relay Therapeutics（纳斯达克代码：RLAY - 获取免费报告）在 5 月 5 日（周二）发布了季度财报。该公司报告每股收益（EPS）为-0.41 美元，低于分析师的共识预期（-0.35 美元）0.06 美元。该季度的营业收入为 300 万美元，而分析师预期为 558 万美元。平均而言，股票研究分析师预计 Relay Therapeutics 在当前年度的每股收益为-1.6 美元。</p>
<h2>Relay Therapeutics 的内部交易</h2>
<p>在其他 Relay Therapeutics 的新闻中，首席财务官 Thomas Catinazzo 在 5 月 14 日（周四）出售了 17,717 股公司的股票。股票以平均价格 12.86 美元出售，总价值为 227,840.62 美元。出售后，首席财务官直接持有 195,178 股公司的股票，价值约为 2,509,989.08 美元。这代表了他们持股比例的 8.32% 的减少。该交易已在提交给证券交易委员会的文件中披露，可以通过此链接访问。在过去三个月中，内部人士已出售价值 532,889 美元的 40,449 股公司股票。内部人士持有公司股票的 5.04%。</p>
<h2>Relay Therapeutics 的机构交易</h2>
<p>对该股票的对冲基金最近修改了持股情况。Sanctuary Advisors LLC 在第一季度将其在 Relay Therapeutics 的持股增加了 1.1%。Sanctuary Advisors LLC 现在拥有 143,816 股公司股票，价值 1,431,000 美元，此前在该期间内又购买了 1,588 股。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Relay Therapeutics 的持股增加了 26.4%。Mirae Asset Global Investments Co. Ltd.现在拥有 8,422 股公司股票，价值 71,000 美元，此前在上个季度又购买了 1,757 股。Abel Hall LLC 在第四季度将其在 Relay Therapeutics 的持股增加了 16.2%。Abel Hall LLC 现在拥有 12,984 股公司股票，价值 110,000 美元，此前在上个季度又购买了 1,809 股。Cresset Asset Management LLC 在第三季度将其在 Relay Therapeutics 的持股增加了 5.0%。Cresset Asset Management LLC 现在拥有 38,932 股公司股票，价值 203,000 美元，此前在该期间内又购买了 1,848 股。最后，Vanguard Personalized Indexing Management LLC 在第三季度将其在 Relay Therapeutics 的持股增加了 8.1%。Vanguard Personalized Indexing Management LLC 现在拥有 27,871 股公司股票，价值 145,000 美元，此前在该期间内又购买了 2,079 股。对冲基金和其他机构投资者持有公司股票的 96.98%。</p>
<h2>Relay Therapeutics 新闻摘要</h2>
<p>以下是本周影响 Relay Therapeutics 的主要新闻：</p>
<ul>
<li>积极情绪：Relay Therapeutics 的 zovegalisib 在血管异常方面显示出良好的早期疗效和耐受性，增强了其更广泛商业机会的案例。文章：Relay Therapeutics 宣布初步临床数据，表明 zovegalisib 在 PIK3CA 驱动的血管异常患者中具有差异化的安全性和疗效潜力</li>
<li>积极情绪：Raymond James 将 RLAY 的目标价格上调至 26 美元，并重申强力买入观点，反映出对管线的乐观情绪。文章：Relay Therapeutics 的目标价格被 Raymond James 上调</li>
<li>中性情绪：该公司表示其现金储备充足，能够持续到 2029 年，这减少了近期融资的担忧，但这在很大程度上被宣布的 1.75 亿美元股票发行所抵消。文章：Relay Therapeutics 宣布拟公开发行普通股</li>
<li>消极情绪：Relay 推出了拟公开发行普通股的计划，这可能会稀释现有股东的股份，并在短期内对股票施加压力。文章：Relay Therapeutics 宣布拟公开发行普通股</li>
</ul>
<h2>关于 Relay Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Relay Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于肿瘤学的精准治疗的发现和开发。公司总部位于马萨诸塞州剑桥，成立于 2016 年，旨在利用综合科学平台针对动态蛋白质运动。Relay Therapeutics 利用计算建模、结构生物学和实验验证来识别能够调节与疾病相关的蛋白质行为的小分子药物候选者。</p>
<p>公司的核心业务活动集中在其专有的药物发现引擎上，该引擎结合了高性能计算——包括分子动力学模拟——与先进的实验技术，如冷冻电子显微镜和生物物理筛选。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 Relay Therapeutics 更好的股票</li>
<li>Strategy Inc.购买比特币并在市场恐慌中寻求分红</li>
<li>Vertical Aerospace：飞行前检查指向突破</li>
<li>Palo Alto Networks 上涨 70%：这波反弹能持续到 6 月吗？</li>
<li>Block 向利润和人工智能的转型引起关注</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxBWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxBWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Relay Therapeutics 吗？</h2>
<p>在考虑 Relay Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Relay Therapeutics 并不在名单上。</p>
<p>虽然 Relay Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RLAY

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

<p>Citizens Jmp 将 Relay Therapeutics (NASDAQ: RLAY) 的目标价格从 19.00 美元上调至 21.00 美元，维持 “市场表现优于大盘” 的评级。这表明与前一交易日收盘价相比，潜在上涨幅度为 73.99%。其他分析师也设定了 21.00 美元至 26.00 美元的目标，整体评级为 “适度买入”，平均目标价格为 22.60 美元</p>

<p>Relay Therapeutics (NASDAQ:RLAY - Get Free Report) had its price objective raised by stock analysts at Citizens Jmp from $19.00 to $21.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a &#34;market outperform&#34; rating on the stock. Citizens Jmp's price target would suggest a potential upside of 73.99% from the stock's previous close.</p>
<div class="lb-trans"><p>Relay Therapeutics（纳斯达克代码：RLAY - 获取免费报告）在周三发布的报告中，Citizens Jmp 的股票分析师将其目标价格从 19.00 美元上调至 21.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “市场表现优于大盘”。Citizens Jmp 的目标价格暗示该股票相较于之前的收盘价有 73.99% 的潜在上涨空间。</p>
</div><p>Get <strong>Relay Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Relay Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Unlocking AI investment opportunities in healthcare</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁医疗保健领域的人工智能投资机会</li>
</ul>
</div><p>Other equities analysts also recently issued reports about the company. UBS Group set a $26.00 target price on Relay Therapeutics in a research report on Tuesday. Citigroup reaffirmed an &#34;outperform&#34; rating on shares of Relay Therapeutics in a research report on Wednesday. HC Wainwright boosted their price target on Relay Therapeutics from $19.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, April 29th. Wells Fargo &amp; Company raised their price objective on Relay Therapeutics from $17.00 to $21.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, April 28th. Finally, Raymond James Financial reaffirmed a &#34;strong-buy&#34; rating on shares of Relay Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $22.60.</p>
<div class="lb-trans"><p>其他股票分析师最近也对该公司发布了报告。瑞银集团在周二的研究报告中将 Relay Therapeutics 的目标价格设定为 26.00 美元。花旗集团在周三的研究报告中重申了对 Relay Therapeutics 股票的 “跑赢大盘” 评级。HC Wainwright 在 4 月 29 日的研究报告中将 Relay Therapeutics 的目标价格从 19.00 美元上调至 25.00 美元，并给予该公司 “买入” 评级。富国银行在 4 月 28 日的研究报告中将 Relay Therapeutics 的目标价格从 17.00 美元上调至 21.00 美元，并给予该股票 “增持” 评级。最后，Raymond James Financial 在周二的报告中重申了对 Relay Therapeutics 股票的 “强力买入” 评级。一位股票研究分析师对该股票给予了 “强力买入” 评级，八位分析师给予 “买入” 评级，一位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价格为 22.60 美元。</p>
</div><p><strong>Read Our Latest Research Report on RLAY</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 RLAY 的最新研究报告</strong></p>
</div><h2>Relay Therapeutics Stock Down 0.2%</h2>
<div class="lb-trans"><h2>Relay Therapeutics 股票下跌 0.2%</h2>
</div><p>RLAY stock opened at $12.07 on Wednesday. The firm has a 50 day moving average of $12.56 and a 200 day moving average of $9.62. The stock has a market capitalization of $2.31 billion, a PE ratio of -7.69 and a beta of 1.74. Relay Therapeutics has a 52 week low of $2.75 and a 52 week high of $17.32.</p>
<div class="lb-trans"><p>周三，RLAY 股票开盘价为 12.07 美元。该公司的 50 日移动平均线为 12.56 美元，200 日移动平均线为 9.62 美元。该股票的市值为 23.1 亿美元，市盈率为-7.69，贝塔值为 1.74。Relay Therapeutics 的 52 周低点为 2.75 美元，52 周高点为 17.32 美元。</p>
</div><p>Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. On average, equities research analysts expect that Relay Therapeutics will post -1.6 earnings per share for the current year.</p>
<div class="lb-trans"><p>Relay Therapeutics（纳斯达克代码：RLAY - 获取免费报告）在 5 月 5 日（周二）发布了季度财报。该公司报告每股收益（EPS）为-0.41 美元，低于分析师的共识预期（-0.35 美元）0.06 美元。该季度的营业收入为 300 万美元，而分析师预期为 558 万美元。平均而言，股票研究分析师预计 Relay Therapeutics 在当前年度的每股收益为-1.6 美元。</p>
</div><h2>Insider Transactions at Relay Therapeutics</h2>
<div class="lb-trans"><h2>Relay Therapeutics 的内部交易</h2>
</div><p>In other Relay Therapeutics news, CFO Thomas Catinazzo sold 17,717 shares of the company's stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $12.86, for a total value of $227,840.62. Following the sale, the chief financial officer directly owned 195,178 shares of the company's stock, valued at approximately $2,509,989.08. This represents a 8.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Insiders have sold 40,449 shares of company stock worth $532,889 in the last three months. Insiders own 5.04% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Relay Therapeutics 的新闻中，首席财务官 Thomas Catinazzo 在 5 月 14 日（周四）出售了 17,717 股公司的股票。股票以平均价格 12.86 美元出售，总价值为 227,840.62 美元。出售后，首席财务官直接持有 195,178 股公司的股票，价值约为 2,509,989.08 美元。这代表了他们持股比例的 8.32% 的减少。该交易已在提交给证券交易委员会的文件中披露，可以通过此链接访问。在过去三个月中，内部人士已出售价值 532,889 美元的 40,449 股公司股票。内部人士持有公司股票的 5.04%。</p>
</div><h2>Institutional Trading of Relay Therapeutics</h2>
<div class="lb-trans"><h2>Relay Therapeutics 的机构交易</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. Sanctuary Advisors LLC grew its holdings in Relay Therapeutics by 1.1% during the first quarter. Sanctuary Advisors LLC now owns 143,816 shares of the company's stock worth $1,431,000 after acquiring an additional 1,588 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Relay Therapeutics by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company's stock worth $71,000 after purchasing an additional 1,757 shares in the last quarter. Abel Hall LLC boosted its position in Relay Therapeutics by 16.2% in the 4th quarter. Abel Hall LLC now owns 12,984 shares of the company's stock worth $110,000 after purchasing an additional 1,809 shares in the last quarter. Cresset Asset Management LLC grew its stake in shares of Relay Therapeutics by 5.0% during the 3rd quarter. Cresset Asset Management LLC now owns 38,932 shares of the company's stock worth $203,000 after purchasing an additional 1,848 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Relay Therapeutics by 8.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company's stock worth $145,000 after purchasing an additional 2,079 shares during the period. Hedge funds and other institutional investors own 96.98% of the company's stock.</p>
<div class="lb-trans"><p>对该股票的对冲基金最近修改了持股情况。Sanctuary Advisors LLC 在第一季度将其在 Relay Therapeutics 的持股增加了 1.1%。Sanctuary Advisors LLC 现在拥有 143,816 股公司股票，价值 1,431,000 美元，此前在该期间内又购买了 1,588 股。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Relay Therapeutics 的持股增加了 26.4%。Mirae Asset Global Investments Co. Ltd.现在拥有 8,422 股公司股票，价值 71,000 美元，此前在上个季度又购买了 1,757 股。Abel Hall LLC 在第四季度将其在 Relay Therapeutics 的持股增加了 16.2%。Abel Hall LLC 现在拥有 12,984 股公司股票，价值 110,000 美元，此前在上个季度又购买了 1,809 股。Cresset Asset Management LLC 在第三季度将其在 Relay Therapeutics 的持股增加了 5.0%。Cresset Asset Management LLC 现在拥有 38,932 股公司股票，价值 203,000 美元，此前在该期间内又购买了 1,848 股。最后，Vanguard Personalized Indexing Management LLC 在第三季度将其在 Relay Therapeutics 的持股增加了 8.1%。Vanguard Personalized Indexing Management LLC 现在拥有 27,871 股公司股票，价值 145,000 美元，此前在该期间内又购买了 2,079 股。对冲基金和其他机构投资者持有公司股票的 96.98%。</p>
</div><h2>Relay Therapeutics News Summary</h2>
<div class="lb-trans"><h2>Relay Therapeutics 新闻摘要</h2>
</div><p>Here are the key news stories impacting Relay Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Relay Therapeutics 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Relay Therapeutics’ zovegalisib showed promising early efficacy and tolerability in vascular anomalies, strengthening the case for a broader commercial opportunity. Article: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies</li>
<li>Positive Sentiment: Raymond James raised its price target on RLAY to $26 and reiterated a strong-buy view, reflecting optimism around the pipeline. Article: Relay Therapeutics price target raised by Raymond James</li>
<li>Neutral Sentiment: The company said it has a sizable cash position and runway into 2029, which reduces near-term financing concerns, but this was largely offset by the announced $175 million stock offering. Article: Relay Therapeutics Announces Proposed Public Offering of Common Stock</li>
<li>Negative Sentiment: Relay launched a proposed public offering of common stock, which can dilute existing shareholders and pressure the stock in the near term. Article: Relay Therapeutics Announces Proposed Public Offering of Common Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Relay Therapeutics 的 zovegalisib 在血管异常方面显示出良好的早期疗效和耐受性，增强了其更广泛商业机会的案例。文章：Relay Therapeutics 宣布初步临床数据，表明 zovegalisib 在 PIK3CA 驱动的血管异常患者中具有差异化的安全性和疗效潜力</li>
<li>积极情绪：Raymond James 将 RLAY 的目标价格上调至 26 美元，并重申强力买入观点，反映出对管线的乐观情绪。文章：Relay Therapeutics 的目标价格被 Raymond James 上调</li>
<li>中性情绪：该公司表示其现金储备充足，能够持续到 2029 年，这减少了近期融资的担忧，但这在很大程度上被宣布的 1.75 亿美元股票发行所抵消。文章：Relay Therapeutics 宣布拟公开发行普通股</li>
<li>消极情绪：Relay 推出了拟公开发行普通股的计划，这可能会稀释现有股东的股份，并在短期内对股票施加压力。文章：Relay Therapeutics 宣布拟公开发行普通股</li>
</ul>
</div><h2>About Relay Therapeutics</h2>
<div class="lb-trans"><h2>关于 Relay Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.</p>
<div class="lb-trans"><p>Relay Therapeutics, Inc 是一家临床阶段的生物技术公司，专注于肿瘤学的精准治疗的发现和开发。公司总部位于马萨诸塞州剑桥，成立于 2016 年，旨在利用综合科学平台针对动态蛋白质运动。Relay Therapeutics 利用计算建模、结构生物学和实验验证来识别能够调节与疾病相关的蛋白质行为的小分子药物候选者。</p>
</div><p>The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.</p>
<div class="lb-trans"><p>公司的核心业务活动集中在其专有的药物发现引擎上，该引擎结合了高性能计算——包括分子动力学模拟——与先进的实验技术，如冷冻电子显微镜和生物物理筛选。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Relay Therapeutics</li>
<li>Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market Fear</li>
<li>Vertical Aerospace: Pre-Flight Checks Point to a Breakout</li>
<li>Palo Alto Networks Up 70%: Can the Rally Last Into June?</li>
<li>Block’s Pivot to Profits and AI Is Turning Heads</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Relay Therapeutics 更好的股票</li>
<li>Strategy Inc.购买比特币并在市场恐慌中寻求分红</li>
<li>Vertical Aerospace：飞行前检查指向突破</li>
<li>Palo Alto Networks 上涨 70%：这波反弹能持续到 6 月吗？</li>
<li>Block 向利润和人工智能的转型引起关注</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxBWQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RLAY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Relay Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Relay Therapeutics 吗？</h2>
</div><p>Before you consider Relay Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Relay Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Relay Therapeutics 并不在名单上。</p>
</div><p>While Relay Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Relay Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Relay Therapeutics (NASDAQ:RLAY) Given New $21.00 Price Target at Citizens Jmp

Market Beat

Relay Therapeutics

医疗业 ETF - Vanguard

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

标普全球医疗股指数 ETF - iShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

美国制药 ETF - iShares

基因改革 ETF - ARK

瑞银集团

花旗

富国银行

瑞杰金融

CITIGROUP INC 6.250 NON CUM SER II PFD WI

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Relay Therapeutics（纳斯达克股票代码：RLAY）被 Citizens Jmp 给予新的 21.00 美元目标价